Gavin Corcoran Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Gavin Corcoran.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Gavin Corcoran. Gavin Corcoran is Chief R&D Officer in Axovant Gene Therapies Ltd. ($AXON) and EVP of R&D in Axovant Sciences Ltd. ($AXON).
Latest Insider Trading Transactions of Gavin Corcoran
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | A | 2.47 | 244,300 | 603,421 | 244,300 | |
Apr 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | A | 2.47 | 244,300 | 603,421 | 244,300 | |
Mar 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | D | 0.00 | 16,001 | 0 | 0 | |
Mar 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Grant | A | 0.00 | 16,001 | 0 | 25,792 | 9.8 K to 25.8 K (+163.43 %) |
Jun 15 2020 | AXON | Axovant Gene Thera ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | D | 0.00 | 16,002 | 0 | 16,001 | |
Jun 15 2020 | AXON | Axovant Gene Thera ... | Corcoran Gavin | Chief R&D Officer | Payment of Exercise | F | 3.46 | 6,211 | 21,490 | 9,791 | 16 K to 9.8 K (-38.81 %) |
Jun 15 2020 | AXON | Axovant Gene Thera ... | Corcoran Gavin | Chief R&D Officer | Grant | A | 0.00 | 16,002 | 0 | 16,002 | 0 to 16 K |
Apr 17 2020 | AXON | Axovant Gene Thera ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 0.00 | 42,400 | 0 | 42,400 | |
Apr 17 2020 | AXON | Axovant Gene Thera ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 3.45 | 63,700 | 219,765 | 63,700 | |
Sep 24 2019 | AXON | Axovant Gene Thera ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 0.00 | 32,003 | 0 | 32,003 | |
Apr 17 2019 | AXON | Axovant Sciences L ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 1.06 | 200,000 | 212,000 | 200,000 | |
Apr 17 2019 | AXON | Axovant Sciences L ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 1.06 | 767,000 | 813,020 | 767,000 | |
Jul 20 2018 | AXON | Axovant Sciences L ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 2.46 | 200,000 | 492,000 | 200,000 | |
Jul 20 2018 | AXON | Axovant Sciences L ... | Corcoran Gavin | EVP of R&D | Option Exercise | A | 2.46 | 250,000 | 615,000 | 250,000 |
Page: 1